Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | CA1 | P00915 | 3/20 | 0.69 |
| ▸ | CA2 | P00918 | 3/20 | 0.69 |
| ▸ | CA12 | O43570 | 2/20 | 0.69 |
| ▸ | CA4 | P22748 | 2/20 | 0.69 |
| ▸ | CA6 | P23280 | 2/20 | 0.69 |
| ▸ | CA7 | P43166 | 2/20 | 0.69 |
| ▸ | CA9 | Q16790 | 2/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.69 |
| ▸ | TPMT | P51580 | 1/20 | 0.69 |
| ▸ | TTR | P02766 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | RARA | P10276 | 2/20 | 0.59 |
| ▸ | RARB | P10826 | 2/20 | 0.59 |
| ▸ | RARG | P13631 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5695675 | 0.90 | ALDH1A1 (0.70) | KDM4ECA1CA2CA12CA4 | |
| SCHEMBL9623633 | 0.90 | HTT (0.67) | KDM4ECA1CA2CA12CA4 | |
| SCHEMBL360580 | 0.88 | KDM4E (0.60) | KDM4ECA1CA2CA12CA4 | |
| Methoxymethane SCHEMBL6861468 | 0.86 | KDM4E (0.77) | KDM4ECA1CA2CA12CA4 | |
| SCHEMBL8742377 | 0.85 | CYP2A6 (0.56) | KDM4ECA1CA2CA12CA4 | |
| SCHEMBL978266 | 0.84 | RARB (0.72) | KDM4ECA1CA2CA12CA4 | |
| SCHEMBL5695670 | 0.84 | KDM4E (0.55) | KDM4ECA1CA2CA12CA4 | |
| SCHEMBL1145072 | 0.83 | KDM4E (0.93) | KDM4ECA1CA2CA12CA4 | |
| SCHEMBL6348501 | 0.83 | KDM4E (0.49) | KDM4ECA1CA2CA12CA4 | |
| SCHEMBL30018459 | 0.83 | KDM4E (0.49) | KDM4ECA1CA2CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105111054-A | Curcumin analogue with enlarged conjugated system and preparation method and application thereof | UNIV LIAOCHENG | 2015-12-02 | — | — | CN | claimed |
| EP-1549598-A4 | NAPTHTHALENE DERIVATIVES WHICH INHIBIT THE CYTOKINE OR BIOLOGICAL ACTIVITY OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) | CORTICAL PTY LTD (AU) | 2008-01-23 | — | — | EP | claimed |
| US-20060106102-A1 | Napththalene derivatives which inhibit the cytokine or biological activity of microphage migration inhibitory factor (mif) | Morand, Eric | 2006-05-18 | — | — | US | claimed |
| CN-1675154-A | Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF) | CORTICAL PTY LTD (AU) | 2005-09-28 | — | — | CN | claimed |
| EP-1549598-A1 | NAPTHTHALENE DERIVATIVES WHICH INHIBIT THE CYTOKINE OR BIOLOGICAL ACTIVITY OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) | Cortical Pty Ltd (AU) | 2005-07-06 | — | — | EP | claimed |
| WO-2003104178-A1 | NAPTHTHALENE DERIVATIVES WHICH INHIBIT THE CYTOKINE OR BIOLOGICAL ACTIVITY OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) | CORTICAL PTY LTD (AU) | 2003-12-18 | — | — | WO | claimed |
| CN-105111054-B | A kind of curcumin analogue of conjugated system increase and its preparation method and application | 聊城大学 | 2017-03-15 | — | — | CN | disclosed |
| CN-105111054-A | Curcumin analogue with enlarged conjugated system and preparation method and application thereof | UNIV LIAOCHENG | 2015-12-02 | — | — | CN | disclosed |
| WO-2012164969-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING CANCER, CONTAINING SUBSTITUTED PHENANTHRENE COMPOUND AS ACTIVE INGREDIENT | 国立大学法人金沢大学 (JP) | 2012-12-06 | — | — | WO | disclosed |
| EP-1549598-A4 | NAPTHTHALENE DERIVATIVES WHICH INHIBIT THE CYTOKINE OR BIOLOGICAL ACTIVITY OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) | CORTICAL PTY LTD (AU) | 2008-01-23 | — | — | EP | disclosed |
| US-20060106102-A1 | Napththalene derivatives which inhibit the cytokine or biological activity of microphage migration inhibitory factor (mif) | Morand, Eric | 2006-05-18 | — | — | US | disclosed |
| US-6989384-B2 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2006-01-24 | — | — | US | disclosed |
| CN-1675154-A | Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF) | CORTICAL PTY LTD (AU) | 2005-09-28 | — | — | CN | disclosed |
| US-4880809-A | HYPOTENSIVE AGENTS, AMIDE DERIVATIVES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| EP-0303286-A1 | 2-Oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines | E.R. Squibb & Sons, Inc. (US) | 1989-02-15 | — | — | EP | disclosed |
| CN-88101588-A | Preparation 1, the method for 4-disubstituted piperazines compounds | — | 1988-11-23 | — | — | CN | disclosed |
| US-4777252-A | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines | E. R. SQUIBB & SONS, INC. (US) | 1988-10-11 | — | — | US | disclosed |
| EP-0284359-A1 | 1,4-Disubstituted piperazine compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1988-09-28 | — | — | EP | disclosed |
| US-4327022-A | Heterocyclic alkyl naphthols | STERLING DRUG INC. (US) | 1982-04-27 | — | — | US | disclosed |
| US-4169108-A | 5(OR 6)-[(Substituted-amino)alkyl]-2,3-naphthalenediols | STERLING DRUG INC. (US) | 1979-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106102-A1 | Napththalene derivatives which inhibit the cytokine or biological activity of microphage migration inhibitory factor (mif) | MIF, ARG1, MSR1 | KDM4E 3166/4885CA1 2883/4885CA2 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.